SELLAS Life Sciences Group, Inc.
Report topline data for the Phase 2a GFH009 study
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 16 Mar 2023
- Due
- 31 Dec 2023
- Delivered
- Q4 2023
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“The topline data for this study are expected in the fourth quarter of 2023.”
What we found
Evidence strength A What the grades mean
The company reported positive initial topline data for the Phase 2a study of GFH009 (also referred to as SLS009) during the fourth quarter of 2023, meeting its stated commitment.
-
A SELLAS Life Sciences Group, Inc. 10-K filed 2024-03-28
“In the fourth quarter of 2023, we completed enrollment in the 45 mg QW dose cohort in the Phase 2a study and reported positive initial topline data.” ✓ confirmed on the page
Market reaction: the shares moved +15.4% against the S&P 500 over the three sessions around the disclosure (27 Mar 2024 to 2 Apr 2024). What this measures
Checked 1 Oct 2026.
Commitment lineage
Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.
- 2 versions
-
Version 1 · original · stated 16 Mar 2023
Deadline 31 Dec 2023 (“fourth quarter of 2023”) · wording expected
-
Version 2 · stated 9 Nov 2023
Deadline 31 Dec 2023 (“by the end of the year”) · target 60 mg · wording firm
“We will share further topline data, including data of patients treated with the recommended Phase 2 dose level of 60 mg, by the end of the year.”
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout
- Indicative materiality
- Medium rules
- Action
- Report
- Deliverable
- Topline data for Phase 2a GFH009 study
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you SELLAS Life Sciences Group, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2023-SLS-002007 · Corrections policy